Get the Stockscreener App
49.59
0.55%
0.3367
Vaxcyte Inc stock is traded at $49.59, with a volume of 476.25K.
It is up +0.55% in the last 24 hours and up +17.26% over the past month.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
See More
Previous Close:
$49.25
Open:
$49.05
24h Volume:
476.25K
Relative Volume:
0.28
Market Cap:
$6.49B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-10.78
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
-0.02%
1M Performance:
+17.26%
6M Performance:
+52.18%
1Y Performance:
-46.00%
1-Day Range:
$48.79
$49.99
1-Week Range:
$47.02
$50.18
52-Week Range:
$27.66
$94.76
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
49.55 | 6.45B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.20 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.91 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.37 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.04 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.36 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-25 | Initiated | Goldman | Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
EBIT per share of Vaxcyte, Inc. – DUS:5VA - TradingView
Mizuho Securities Sticks to Their Buy Rating for Vaxcyte (PCVX) - The Globe and Mail
Vaxcyte (PCVX): Evaluating Valuation After a 48% Three-Month Share Price Rebound - Yahoo Finance
How Vaxcyte Inc. stock reacts to Fed rate cutsWeekly Trade Report & Free Technical Pattern Based Buy Signals - newser.com
Is Vaxcyte Inc. stock vulnerable to regulatory risksEarnings Growth Report & Risk Managed Investment Entry Signals - newser.com
Will Vaxcyte Inc. stock continue upward momentumQuarterly Trade Review & Accurate Trade Setup Notifications - newser.com
Is Vaxcyte Inc. (5VA) stock a top hedge fund pickJuly 2025 Action & Momentum Based Trading Ideas - newser.com
Vaxcyte stock price target raised to $77 from $60 at Leerink Partners By Investing.com - Investing.com South Africa
Vaxcyte stock price target raised to $77 from $60 at Leerink Partners - Investing.com Australia
PCVX: 31-Valent vaccine nears phase III, targeting major market growth and expanded global demand - TradingView
Vaxcyte (PCVX) Price Target Decreased by 17.52% to 83.49 - MSN
What analyst consensus says on Vaxcyte Inc. stockTrade Entry Report & High Conviction Trade Alerts - newser.com
(PCVX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Can momentum traders help lift Vaxcyte Inc.July 2025 Action & Precise Swing Trade Entry Alerts - newser.com
Is Vaxcyte Inc. stock poised for growthEarnings Trend Report & Daily Technical Forecast Reports - newser.com
Will Vaxcyte Inc. benefit from macro trendsPortfolio Risk Summary & Safe Capital Allocation Plans - newser.com
Vaxcyte, Inc.Common Stock (NQ: PCVX - Markets Financial Content
Vaxcyte Inc Stock Analysis and ForecastStock Split Announcements & High Profit Portfolio Growth - earlytimes.in
Vaxcyte stock up on results from mid-stage trial of its pneumococcal vaccine - MSN
Vaxcyte Inc. (PCVX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vaxcyte (BIT:1PCVX) Price Target Decreased by 15.42% to 72.37 - Nasdaq
Is Vaxcyte’s (PCVX) Aggressive R&D Spend Still Justified Amid Widening Losses? - simplywall.st
Should you wait for a breakout in Vaxcyte Inc.July 2025 Review & High Conviction Investment Ideas - newser.com
Quantitative breakdown of Vaxcyte Inc. recent move2025 Technical Overview & Real-Time Market Sentiment Alerts - newser.com
Has Vaxcyte Inc. found a price floorBond Market & Smart Investment Allocation Insights - newser.com
Can Vaxcyte Inc. (5VA) stock attract analyst upgrades2025 Performance Recap & AI Powered Buy and Sell Recommendations - newser.com
Using data tools to time your Vaxcyte Inc. exitChart Signals & Daily Market Momentum Tracking - newser.com
Vaxcyte, Inc. (5VA.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Will Vaxcyte Inc. stock benefit from commodity prices2025 Price Momentum & Risk Controlled Stock Alerts - newser.com
Vaxcyte’s Stock Juggle: Opportunity or Risk? - StocksToTrade
What moving averages say about Vaxcyte Inc.Market Rally & Reliable Breakout Forecasts - newser.com
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vaxcyte Inc Stock (PCVX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):